The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin β3–p38 MAPK signalling
Open accessAbstract
Metastasis is the leading cause of breast cancer-related deaths. Cancer-associated fibroblasts (CAFs), the predominant stromal cell type in the breast tumour microenvironment, may contribute to cancer progression through interaction with tumour cells. Nonetheless, little is known about the details of the underlying mechanism. Here we found that interaction of interleukin 32 (IL32) with integrin β3 (encoded by ITGB3; a member of the integrin family) mediating the cross-talk between CAFs and breast cancer cells plays a crucial role in CAF-induced breast tumour invasiveness. IL32, an 'RGD' motif-containing cytokine, was found to be abundantly expressed in CAFs. Integrin β3 turned out to be up-regulated in breast cancer cells during epithelial-mesenchymal transition (EMT). CAF-derived IL32 specifically bound to integrin β3 through the RGD motif, thus activating intracellular downstream p38 MAPK signalling in breast cancer cells. This signalling increased the expression of EMT markers (fibronectin, N-cadherin, and vimentin) and promoted tumour cell invasion. Counteracting IL32 activity, a knockdown of IL32 or integrin β3 led to specific inactivation of p38 MAPK signalling in tumour cells. Blockage of the p38 MAPK pathway also diminished IL32-induced expression of EMT markers and breast cancer cell invasion and metastasis. Thus, our data indicate that CAF-secreted IL32 promotes breast cancer cell invasion and metastasis via integrin β3-p38 MAPK signalling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
MiR-30a-5p Suppresses Tumor Metastasis of Human Colorectal Cancer by Targeting ITGB3
Wei, W., Yang, Y., Cai, J., Cui, K., Li, R.-X., Wang, H., Shang, X., & Wei, D. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447823 · Cited by 96
RetractedIntegrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Epithelial-Mesenchymal Transition: At the Crossroads of Development and Tumor Metastasis
Yang, J., & Weinberg, R. A. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.05.009 · Cited by 3,012
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1477 · Cited by 1,765
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753
Ansieau, S., Bastid, J., Doreau, A., Morel, A.-P., Bouchet, B. P., Thomas, C., Fauvet, F., Puisieux, I., Doglioni, C., Piccinin, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.005 · Cited by 715
Kim, S.-H., Han, S.-Y., Azam, T., Yoon, D.-Y., & Dinarello, C. A. (2005) · Immunity · doi:10.1016/j.immuni.2004.12.003 · Cited by 535
Ishii, G., Ochiai, A., & Neri, S. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.07.007 · Cited by 434
Hartman, Z. C., Poage, G. M., den Hollander, P., Tsimelzon, A., Hill, J., Panupinthu, N., Zhang, Y., Mazumdar, A., Hilsenbeck, S. G., Mills, G. B., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4524-t · Cited by 409
Nishiuchi, R., Takagi, J., Hayashi, M., Ido, H., Yagi, Y., Sanzen, N., Tsuji, T., Yamada, M., & Sekiguchi, K. (2006) · Matrix Biology · doi:10.1016/j.matbio.2005.12.001 · Cited by 385
‘Cancer associated fibroblasts’ – more than meets the eye
Madar, S., Goldstein, I., & Rotter, V. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.004 · Cited by 362
Integrin signalling adaptors: not only figurants in the cancer story
Cabodi, S., del Pilar Camacho-Leal, M., Di Stefano, P., & Defilippi, P. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2967 · Cited by 291
Integrin inactivators: balancing cellular functions in vitro and in vivo
Bouvard, D., Pouwels, J., De Franceschi, N., & Ivaska, J. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3599 · Cited by 234
Zhao, B., Han, H., Chen, J., Zhang, Z., Li, S., Fang, F., Zheng, Q., Ma, Y., Zhang, J., Wu, N., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.08.030 · Cited by 199
Liu, M., Casimiro, M. C., Wang, C., Shirley, L. A., Jiao, X., Katiyar, S., Ju, X., Li, Z., Yu, Z., Zhou, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910009106 · Cited by 171
Self-citationYuan, J., Liu, M., Yang, L., Tu, G., Zhu, Q., Chen, M., Cheng, H., Luo, H., Fu, W., Li, Z., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0579-y · Cited by 128
Self-citationαvβ3‐ or α5β1‐Integrin‐Selective Peptidomimetics for Surface Coating
Mas‐Moruno, C., Fraioli, R., Rechenmacher, F., Neubauer, S., Kapp, T. G., & Kessler, H. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201509782 · Cited by 128
Li, W., Sun, W. Y., Liu, L., Yang, F., Li, Y., Chen, Y., Fang, J., Zhang, W., Wu, J., & Zhu, Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902667 · Cited by 124
Talin activates integrins by altering the topology of the β transmembrane domain
Kim, C., Ye, F., Hu, X., & Ginsberg, M. H. (2012) · The Journal of Cell Biology · doi:10.1083/jcb.201112141 · Cited by 109
Expression of IL-32 in Human Lung Cancer Is Related to the Histotype and Metastatic Phenotype
Sorrentino, C., & Carlo, E. D. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200903-0400oc · Cited by 108
Nold‐Petry, C. A., Rudloff, I., Baumer, Y., Ruvo, M., Marasco, D., Botti, P., Farkas, L., Cho, S., Zepp, J. A., Azam, T., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202802 · Cited by 96
Peng, Q., Zhao, L., Hou, Y., Sun, Y., Wang, L., Luo, H., Peng, H., & Liu, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060321 · Cited by 93
Self-citationIL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals
Oh, J., Cho, M.-C., Kim, J., Lee, S. Y., Kim, H. J., Park, E. S., Ban, J. O., Kang, J.-W., Lee, D.-H., Shim, J.-H., et al. (2011) · Oncogene · doi:10.1038/onc.2011.52 · Cited by 93
Yang, J., Hou, Y., Zhou, M., Wen, S., Zhou, J., Xu, L., Tang, X., Du, Y.-E., Hu, P., & Liu, M. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.12.004 · Cited by 92
Self-citationAntagonizing Integrin β3 Increases Immunosuppression in Cancer
Su, X., Esser, A. K., Amend, S. R., Xiang, J., Xu, Y., Ross, M. H., Fox, G. C., Kobayashi, T., Steri, V., Roomp, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2663 · Cited by 91
Heinhuis, B., Koenders, M. I., van den Berg, W. B., Netea, M. G., Dinarello, C. A., & Joosten, L. A. B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.288290 · Cited by 83
Shao, N., Lu, Z., Zhang, Y., Wang, M., Li, W., Hu, Z., Wang, S., & Lin, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.009 · Cited by 78
Hasegawa, H., Thomas, H. J., Schooley, K., & Born, T. L. (2010) · Cytokine · doi:10.1016/j.cyto.2010.09.002 · Cited by 71
Liu, Z., Han, L., Dong, Y., Tan, Y., Li, Y., Zhao, M., Xie, H., Ju, H., Wang, H., Zhao, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6730 · Cited by 62
Self-citationSon, D. J., Jung, Y. Y., Seo, Y. S., Park, H., Lee, D. H., Kim, S., Roh, Y., Han, S., Yoon, D. Y., & Hong, J. T. (2017) · Theranostics · doi:10.7150/thno.18407 · Cited by 54
Chen, J., Wang, S., Su, J., Chu, G., You, H., Chen, Z., Chen, B., Zhou, M., & Sun, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s103581 · Cited by 47
LncRNA expression signatures of twist-induced epithelial-to-mesenchymal transition in MCF10A cells
Hu, P., Yang, J., Hou, Y., Zhang, H., Zeng, Z., Zhao, L., Yu, T., Tang, X., Tu, G., Cui, X., et al. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.10.001 · Cited by 45
Self-citationc-Ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion
Wang, L., Hou, Y., Sun, Y., Zhao, L., Tang, X., Hu, P., Yang, J., Zeng, Z., Yang, G., Cui, X., et al. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.08.007 · Cited by 43
Self-citationDo, M. T., Chai, T. F., Casey, P. J., & Wang, M. (2017) · Oncogene · doi:10.1038/onc.2017.183 · Cited by 36
Hong, S.-K., Park, J., Kwon, O., Kim, K.-T., Bae, G.-Y., & Cha, H. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.012 · Cited by 30
Spermine, a Molecular Switch Regulating EGFR, Integrin β3, Src, and FAK Scaffolding
Ray, R., Li, C.-Y., Bhattacharya, S., Naren, A., & Johnson, L. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.12.016 · Cited by 24
Nasulewicz‐Goldeman, A., Uszczyńska-Ratajczak, B., Szczaurska‐Nowak, K., & Wietrzyk, J. (2012) · Oncology Reports · doi:10.3892/or.2012.1963 · Cited by 24
Wang, G., Wang, X., Huang, X., Yang, H., Pang, S.-Q., Xie, X., Zeng, S., Lin, J., & Diao, Y. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0365-7 · Cited by 10
Cited by
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
Zhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Breast cancer heterogeneity and its implication in personalized precision therapy
Guo, L., Kong, D., Liu, J., Zhan, L., Luo, L., Zheng, W., Zheng, Q., Chen, C., & Sun, S. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00363-1 · Cited by 327
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Qi, R., Bai, Y., Li, K., Liu, N., Xu, Y., Dal, E., Wang, Y., Lin, R., Wang, H., Liu, Z., et al. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.100960 · Cited by 307
Metadata
- Authors
- Wen, S., Hou, Y., Fu, L., Xi, L., Yang, D., Zhao, M., Qin, Y., Sun, K., Teng, Y., & Liu, M.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 442
- Pages
- 320-332
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2898316705
- Cited by
- 344
- References
- 44
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.